Enter drug's generic or brand name below. Results will appear here. Note: all drug related information obtained on this page is provided by RX List.
Using the RX LIST database:
(1) Enter the drug name in the search box below and hit ENTER
(2) The rx list web site will open here with the drug search completed. Next, scroll down the page to locate the link to the drug you are searching for and then click on the link.
Beleodaq is a histone deacetylase inhibitor with a sulfonamide-hydroxamide structure. The chemical name of belinostat is (2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide. The structural formula is as follows:
 |
The molecular formula is C15H14N2O4S and the molecular weight is 318.35 g/mol.
Belinostat is a white to off-white powder. It is slightly soluble in distilled water (0.14 mg/mL) and polyethylene glycol 400 (about 1.5 mg/mL), and is freely soluble in ethanol (> 200 mg/mL). The pKa values are 7.87 and 8.71 by potentiometry and 7.86 and 8.59 by UV.
Beleodaq (belinostat) for injection is supplied as a sterile lyophilized yellow powder containing 500 mg belinostat as the active ingredient. Each vial also contains 1000 mg L-Arginine, USP as an inactive ingredient. The drug product is supplied in a single-dose 30 mL clear glass vial with a coated stopper and aluminum crimp seal with “flip-off” cap. Beleodaq is intended for intravenous administration after reconstitution with 9 mL Sterile Water for injection, and the reconstituted solution is further diluted with 250 mL of sterile 0.9% Sodium Chloride injection prior to infusion [See DOSAGE AND ADMINISTRATION].
Beleodaq is indicated for the treatment of adult patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
This indication is approved under accelerated approval based on tumor response rate and duration of response [see Clinical Studies]. An improvement in survival or disease-related symptoms has not been established. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trial.
The recommended dosage of Beleodaq is 1,000 mg/m² administered over 30 minutes by intravenous infusion once daily on Days 1 through 5 of a 21-day cycle. Cycles can be repeated every 21 days until disease progression or unacceptable toxicity.
Table 1 displays the recommended Beleodaq dosage modifications for hematologic and non-hematologic toxicities. Base dosage adjustments for thrombocytopenia and neutropenia on platelet and absolute neutrophil nadir (lowest value) counts in the preceding cycle of therapy.
Monitor complete blood counts at baseline and weekly. Perform serum chemistry tests, including renal and hepatic functions prior to the start of the first dose of each cycle.
Table 1: Dosage Modifications for Hematologic and Non-Hematologic Toxicities
| Dosage Modification | |
| Dosage Modifications due to Hematologic Toxicities | |
| Platelet count ≥ 25 x 109/L and nadir ANC ≥ 0.5 x 109/L | No Change |
| Nadir ANC < 0.5 x 109/L (any platelet count) | Decrease dosage by 25% (750 mg/m²) |
| Platelet count < 25 x 109/L (any nadir ANC) | |
| Dosage Modifications due to Non-Hematologic Toxicities | |
| Any CTCAE Grade 3 or 4 adverse reactiona | Decrease dosage by 25% (750 mg/m²) |
| Recurrence of CTCAE Grade 3 or 4 adverse reaction after two dosage reductions | Discontinue Beleodaq |
| a For nausea, vomiting, and diarrhea, dose modification may not be necessary if the duration is less than 7 days with supportive management | |
Beleodaq dosage in patients with moderate hepatic impairment (total bilirubin > 1.5 to 3 x ULN, any aspartate aminotransferase (AST)) is 500 mg/m² administered over 30 minutes by intravenous infusion once daily on Days 1 through 5 of a 21-day cycle. Avoid use of Beleodaq in patients with severe hepatic impairment (total bilirubin > 3 x ULN, any AST). No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin ≤ 1.5 x ULN, any AST). Hepatic impairment is defined per the National Cancer Institute Organ Dysfunction Working Group.
Beleodaq dosage in patients with moderate renal impairment (creatine clearance [CLcr] 30 to <60 mL/min) is 500 mg/m² administered over 30 minutes by intravenous infusion once daily on Days 1 through 5 of a 21-day cycle. Avoid use of Beleodaq in patients with severe renal impairment (CLcr < 30 mL/min). No dosage adjustment is recommended for patients with mild renal impairment (CLcr 60 to < 90 mL/min).
Reduce the starting dose of Beleodaq to 750 mg/m² in patients known to be homozygous for the UGT1A1*28 allele [see CLINICAL PHARMACOLOGY].
Avoid concomitant use of Beleodaq with UGT1A1 inhibitors. If concomitant use of a UGT1A1 inhibitor is unavoidable, reduce the Beleodaq dosage by 25% as shown in Table 2.
Table 2: Dosage Modifications for Concomitant Use with a UGT1A1 Inhibitor
| Beleodaq Starting Dosage | Beleodaq Modified Dosage |
| 1,000 mg/m² | 750 mg/m² |
| 750 mg/m² | 562.5 mg/m² |
| 500 mg/m² | Interrupt Beleodaq treatment for the duration of UGT1A1 inhibitor use. After discontinuation of a UGT1A1 inhibitor of 5 half-lives, resume the Beleodaq dosage that was taken prior to initiating the UGT1A1 inhibitor. |
Beleodaq is a hazardous drug. Follow applicable special handling and disposal procedures.1
For injection: 500 mg, lyophilized powder in single-dose vial for reconstitution
Beleodaq (belinostat) for injection is supplied in single vial cartons; each clear vial contains sterile, lyophilized powder equivalent to 500 mg belinostat.
NDC 72893-002-01: Individual carton of Beleodaq single-dose vial containing 500 mg belinostat.
Store Beleodaq (belinostat) for injection at room temperature 20°C to 25°C (68°F to 77°F). Excursions are permitted between 15°C and 30°C (59°F and 86°F). Retain in original package until use. [see USP Controlled Room Temperature].
Beleodaq is a hazardous drug. Follow special handling and disposal procedures.1
REFERENCES
1 OSHA Hazardous Drugs. OSHA. https://www.osha.gov/SLTC/hazardousdrugs/index.html
Manufactured by: Cenexi Laboratories Thissen SA, Braine I'Alleud, 1420, Belgium. Manufactured for: Acrotech Biopharma Inc, East Windsor, NJ 08520 USA. Revised: Nov 2024
The following clinically significant adverse reactions are described in more detail in other sections of the prescribing information.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of Beleodaq may not reflect the rates observed in practice.
The safety of Beleodaq was evaluated in 129 patients with relapsed or refractory PTCL in the single arm clinical trial in which patients were administered Beleodaq at a dosage of 1,000 mg/m² administered over 30 minutes by IV infusion once daily on Days 1 through 5 of a 21-day cycle [see Clinical Studies]. The median duration of treatment was 2 cycles (range 1 – 33 cycles).
The most common adverse reactions observed in the trial of patients with relapsed or refractory PTCL treated with Beleodaq were nausea, fatigue, pyrexia, anemia, and vomiting [see Clinical Studies]. Table 3 summarizes the adverse reactions regardless of causality from the trial in patients with relapsed or refractory PTCL.
Table 3: Adverse Reactions Occurring in ≥ 10% of Patients with Relapsed or Refractory PTCL (NCI-CTC Grade 1-4)
| Adverse Reactions | Percentage of Patients (%) (N=129) |
|
| All Grades | Grade 3 or 4 | |
| All Adverse Reactions | 97 | 61 |
| Nausea | 42 | 1 |
| Fatigue | 37 | 5 |
| Pyrexia | 35 | 2 |
| Anemia | 32 | 11 |
| Vomiting | 29 | 1 |
| Constipation | 23 | 1 |
| Diarrhea | 23 | 2 |
| Dyspnea | 22 | 6 |
| Rash | 20 | 1 |
| Peripheral Edema | 20 | 0 |
| Cough | 19 | 0 |
| Thrombocytopenia | 16 | 7 |
| Pruritus | 16 | 3 |
| Chills | 16 | 1 |
| Increased Blood Lactate Dehydrogenase | 16 | 2 |
| Decreased Appetite | 15 | 2 |
| Headache | 15 | 0 |
| Infusion Site Pain | 14 | 0 |
| Hypokalemia | 12 | 4 |
| Prolonged QT | 11 | 4 |
| Abdominal pain | 11 | 1 |
| Hypotension | 10 | 3 |
| Phlebitis | 10 | 1 |
| Dizziness | 10 | 0 |
| Note: Adverse reactions are listed by order of incidence in the “All Grades” category first, then by incidence in “ the Grade 3 or 4” category; Measured by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 3.0 | ||
Sixty-one patients (47.3%) experienced serious adverse reactions while taking Beleodaq or within 30 days after their last dose of Beleodaq . The most common serious adverse reactions (> 2%) were pneumonia, pyrexia, infection, anemia, increased creatinine, thrombocytopenia, and multi-organ failure. One treatment-related death associated with hepatic failure was reported in the trial.
One patient with baseline hyperuricemia and bulky disease experienced Grade 4 tumor lysis syndrome during the first cycle of treatment and died due to multi-organ failure. A treatment-related death from ventricular fibrillation was reported in another monotherapy clinical trial with Beleodaq. ECG analysis did not identify QTc prolongation.
Twenty-five patients (19.4%) discontinued treatment with Beleodaq due to adverse reactions. The adverse reactions reported most frequently as the reason for discontinuation of treatment included anemia, febrile neutropenia, fatigue, and multi-organ failure.
In the trial, dosage adjustments due to adverse reactions occurred in 12% of Beleodaq-treated patients.
Avoid concomitant administration of Beleodaq with UGT1A1inhibitors. If concomitant use of a UGT1A1 inhibitor is unavoidable, modify the Beleodaq dose [see DOSAGE AND ADMINISTRATION].
Belinostat is primarily metabolized by UGT1A1. Concomitant use with a UGT1A1 inhibitor increases belinostat exposure [see CLINICAL PHARMACOLOGY], which may increase the risk of Beleodaq adverse reactions.
Included as part of the PRECAUTIONS section.
Beleodaq can cause thrombocytopenia, leukopenia (neutropenia and lymphopenia), and/or anemia; monitor blood counts weekly during treatment, and modify dosage as necessary [see DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS].
Serious and sometimes fatal infections, including pneumonia and sepsis, have occurred with Beleodaq. Do not administer Beleodaq to patients with an active infection. Patients with a history of extensive or intensive chemotherapy may be at higher risk of life threatening infections [see ADVERSE REACTIONS].
Beleodaq can cause fatal hepatotoxicity and liver function test abnormalities [see ADVERSE REACTIONS]. Monitor liver function tests before treatment and before the start of each cycle. Interrupt or adjust dosage until recovery, or permanently discontinue Beleodaq based on the severity of the hepatic toxicity [see DOSAGE AND ADMINISTRATION and CLINICAL PHARMACOLOGY].
Tumor lysis syndrome has occurred in Beleodaq-treated patients in the clinical trial of patients with relapsed or refractory PTCL [see Clinical Studies]. Monitor patients with advanced stage disease and/or high tumor burden and take appropriate precautions [see ADVERSE REACTIONS].
Nausea, vomiting and diarrhea occur with Beleodaq [see ADVERSE REACTIONS] and may require the use of antiemetic and antidiarrheal medications.
Based on its mechanism of action and findings of genotoxicity, Beleodaq can cause fetal harm when administered to a pregnant woman [see CLINICAL PHARMACOLOGY and Nonclinical Toxicology]. Advise pregnant women of the risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with Beleodaq and for 6 months after the last dose [see Use In Specific Populations]. Advise males with female partners of reproductive potential to use effective contraception during treatment with Beleodaq and for 3 months after the last dose.
Physicians should discuss the FDA approved PATIENT INFORMATION Leaflet with patients prior to treatment with Beleodaq. Instruct patients to read the Patient Information Leaflet carefully.
Advise the patient or the caregiver to read the FDA-approved patient labeling (Patient Information).
Advise patients or their caregivers:
Carcinogenicity studies have not been performed with belinostat.
Belinostat was genotoxic in a bacterial reverse mutation test (AMES assay), an in vitro mouse lymphoma cell mutagenesis assay, and an in vivo rat micronucleus assay.
Beleodaq may impair male fertility. Fertility studies using belinostat were not conducted. However, belinostat effects on male reproductive organs observed during the 24-week repeat-dose dog toxicology study included reduced organ weights of the testes/epididymides that correlated with a delay in testicular maturation.
Based on its mechanism of action, Beleodaq can cause teratogenicity and/or embryo-fetal lethality because it is genotoxic and targets actively dividing cells [see CLINICAL PHARMACOLOGY and Nonclinical Toxicology]. There are no available data on Beleodaq use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. No animal reproduction studies were conducted with Beleodaq. Advise pregnant women of the potential risk to a fetus.
The estimated background risk of major birth defects and miscarriage for the indicated population(s) is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.
There are no data on the presence of belinostat in human milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with Beleodaq, and for 2 weeks after the last dose.
Beleodaq can cause embryo-fetal harm when administered to a pregnant woman [see Use In Specific Populations].
Pregnancy testing is recommended for females of reproductive potential prior to initiating Beleodaq.
Females
Advise females of reproductive potential to use effective contraception during treatment with Beleodaq and for 6 months after the last dose.
Males
Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with Beleodaq and for 3 months after the last dose [see Nonclinical Toxicology].
Males
Based on findings from animal studies, Beleodaq may impair male fertility. The reversibility of the effect on fertility is unknown [see Nonclinical Toxicology].
The safety and effectiveness of Beleodaq in pediatric patients have not been established.
In the single-arm trial, 48% of patients (N = 62) were ≥ 65 years of age and 10% of patients (N=13) were ≥ 75 years of age [see Clinical Studies]. The median age of the trial population was 63 years. Patients ≥ 65 years of age had a higher response rate to Beleodaq treatment than patients < 65 years of age (36% versus 16%) while no meaningful differences in response rate were observed between patients ≥ 75 years of age and those < 75 years of age. No clinically meaningful differences in serious adverse reactions were observed in patients based on age (< 65 years compared with ≥ 65 years or < 75 years of age compared with ≥ 75 years of age).
No dosage adjustment is recommended for patients with mild hepatic impairment (total bilirubin ≤ 1.5 x ULN, any AST). Reduce the Beleodaq dosage in patients with moderate hepatic impairment (total bilirubin > 1.5 to 3 x ULN, any AST) [see DOSAGE AND ADMINISTRATION]. Avoid use of Beleodaq in patients with severe hepatic impairment (total bilirubin > 3 x ULN, any AST) [see CLINICAL PHARMACOLOGY].
Belinostat is metabolized in the liver, moderate hepatic impairment (total bilirubin > 1.5 to 3 x ULN, any AST) and severe hepatic impairment (total bilirubin > 3 x ULN, any AST) increases belinostat exposure [see CLINICAL PHARMACOLOGY], which may increase the risk of Beleodaq adverse reactions.
No dosage adjustment is recommended for patients with mild renal impairment (CLcr 60 to < 90 mL/min). Reduce the Beleodaq dosage in in patients with moderate renal impairment (CLcr 30 to <60 mL/min) [see DOSAGE AND ADMINISTRATION]. Avoid use of Beleodaq in patients with severe renal impairment (CLcr < 30 mL/min).
Moderate renal impairment (CLcr 30 to <60 mL/min) increases belinostat exposure [see CLINICAL PHARMACOLOGY], which may increase the risk of Beleodaq adverse reactions. The effect of severe renal impairment (CLcr < 30 mL/min) on belinostat pharmacokinetics is unknown [see CLINICAL PHARMACOLOGY].
No specific information is available on the treatment of overdosage of Beleodaq. There is no antidote for Beleodaq and it is not known if Beleodaq is dialyzable. If an overdose occurs, general supportive measures should be instituted as deemed necessary by the treating physician. The elimination half-life of belinostat is 1.1 hours [see CLINICAL PHARMACOLOGY].
None
Beleodaq is a histone deacetylase (HDAC) inhibitor. HDACs catalyze the removal of acetyl groups from the lysine residues of histones and some non-histone proteins. In vitro, belinostat caused the accumulation of acetylated histones and other proteins, inducing cell cycle arrest and/or apoptosis of some transformed cells. Belinostat shows preferential cytotoxicity towards tumor cells compared to normal cells. Belinostat inhibited the enzymatic activity of histone deacetylases at nanomolar concentrations (<250 nM).
Belinostat exposure-response relationships and the time course of pharmacodynamic response are not fully characterized.
Multiple clinical trials have been conducted with Beleodaq, in many of which ECG data were collected and analyzed by a central laboratory. Analysis of clinical ECG and belinostat plasma concentration data demonstrated no meaningful effect of Beleodaq on cardiac repolarization. None of the trials showed any clinically relevant changes caused by Beleodaq on heart rate, PR duration or QRS duration as measures of autonomic state, atrio-ventricular conduction or depolarization; there were no cases of Torsades de Pointes.
The pharmacokinetic characteristics of belinostat were analyzed from pooled data from phase ½ clinical studies that used doses of belinostat ranging from 150 to 1200 mg/m² (0.15 to 1.2 times the approved recommended dosage).
The mean belinostat volume of distribution approaches total body water, indicating that belinostat has limited body tissue distribution. In vitro plasma studies have shown that between 92.9% and 95.8% of belinostat is bound to protein in an equilibrium dialysis assay, and was independent of belinostat plasma concentrations from 500 to 25,000 ng/mL.
Belinostat elimination half-life is 1.1 hours with a total mean plasma clearance of 1240 mL/min. The total clearance approximates average hepatic blood flow (1500 mL/min), suggesting high hepatic extraction (clearance being flow dependent).
Belinostat is primarily metabolized by hepatic UGT1A1. Belinostat also undergoes hepatic metabolism by CYP2A6, CYP2C9, and CYP3A4 enzymes.
Following a single dose of radiolabeled belinostat (100 μCi, 1500 mg) administered as a 30-minute intravenous infusion in patients with recurrent or progressive malignancy, fecal excretion accounted for a mean (± SD) of 9.7% (± 6.5%) of the administered radioactive belinostat dose over 168 hours. The mean (± SD) of the administered radioactive belinostat dose that was excreted in urine over 168 hours was 84.8% (± 9.8%), of which unchanged belinostat accounted for only 1.7%.
Belinostat steady state clearance decreased and AUC increased as a function of the degree of liver dysfunction, but were unchanged for Cmax, half-life and apparent volume of distribution. Mean belinostat clearance was reduced by 18% in mild (total bilirubin ≤ ULN and AST >ULN, or total bilirubin >1 to 1.5 x ULN), 24% in moderate (total bilirubin > 1.5 to 3 times ULN and any value for AST) and 33% in severe hepatic impairment (total bilirubin > 3 to 10 times ULN and any value for AST). Increases in belinostat exposure were correlated with worsening liver function, but there was no obvious relationship between exposure and DLTs during the first cycle of therapy.
Belinostat Cmax increased by 1.7-fold, AUC0-∞ by 1.3-fold and CLtot was unchanged in patients with mild renal impairment (CLcr 60 to <90 ml/min). Belinostat Cmax and AUC0-∞ increased by 1.7-fold and CLtot decreased by 26% in patients with moderate renal impairment (CLcr 30 < 60 ml/min). The effect of severe renal impairment (CLcr < 30 mL/min) on belinostat pharmacokinetics is unknown.
UGT1A1 Inhibitors
Belinostat t½ increased by 1.5-fold, AUC0-inf increased by 1.4-fold, Cmax decreased by 33%, and renal excretion increased by 2.5-fold following concomitant administration with atazanavir (UGT1A1 inhibitor), but there was minimal change in steady state clearance. There was minimal change in belinostat glucuronide Cmax, AUC0-24; however, belinostat glucuronide excretion decreased by 48%.
Warfarin
No clinically significant differences in the pharmacokinetics of R- or S-warfarin were observed when used concomitantly with belinostat.
CYP450 Enzymes
Belinostat and its metabolites are CYP2C8 and CYP2C9 inhibitors.
Transporter Systems
Belinostat is a glycoprotein (P-gp) substrate but is not a P-gp inhibitor.
UGT1A1 activity is reduced in individuals with genetic polymorphisms that lead to reduced enzyme activity such as the UGT1A1*28 polymorphism. Approximately 20% of the Black population, 10% of the White population, and 2% of the Asian population are homozygous for the UGT1A1*28 allele. Additional reduced function alleles may be more prevalent in specific populations.
Because belinostat is primarily (80-90%) metabolized by UGT1A1, the clearance of belinostat could be decreased in patients with reduced UGT1A1 activity (e.g., patients with UGT1A1*28 allele). Reduce the starting dose of Beleodaq to 750 mg/m² in patients known to be homozygous for the UGT1A1*28 allele to minimize dose limiting toxicities [see DOSAGE AND ADMINISTRATION].
In an open-label, single-arm, non-randomized international trial conducted at 62 centers, 129 patients with relapsed or refractory PTCL were treated with Beleodaq 1,000 mg/m² administered over 30 minutes via IV infusion once daily on Days 1 through 5 of a 21-day cycle. There were 120 patients who had histologically confirmed PTCL by central review evaluable for efficacy. Patients were treated with repeat cycles every three weeks until disease progression or unacceptable toxicity.
Efficacy was evaluated using response rate (complete response and partial response) as assessed by an independent review committee (IRC) using the International Workshop Criteria (IWC) (Cheson 2007). Response assessments were evaluated every 6 weeks for the first 12 months and then every 12 weeks until 2 years from the start of study treatment. Duration of response was measured from the first day of documented response to disease progression or death. Response and progression of disease were evaluated by the IRC using the IWC.
Table 4 summarizes the baseline demographic and disease characteristics of the study population, who were evaluable for efficacy.
Table 4: Baseline Patient Characteristics (PTCL Population)
| Characteristics | Evaluable Patients (N=120) |
| Age (years) | |
| Median (range) | 64 (29 - 81) |
| Sex, % | |
| Male | 52 |
| Female | 48 |
| Race, % | |
| White | 88 |
| Black | 6 |
| Asian | 3 |
| Latin | 3 |
| Other | 2 |
| PTCL Subtype Based on Central Diagnosis, % | |
| PTCL Unspecified (NOS) | 64 |
| Angioimmunoblastic T-cell lymphoma (AITL) | 18 |
| ALK-1 negative anaplastic large cell lymphoma (ALCL) | 11 |
| Other | 7 |
| Baseline Platelet Count, % | |
| ≥100,000/μL | 83 |
| <100,000/μL | 17 |
| ECOG Performance Status, % | |
| 0 | 34 |
| 1 | 43 |
| 2 | 22 |
| 3 | 1 |
| Median Time (months) from Initial PTCL Diagnosis (Range) | 12 (2.6 - 266.4) |
| Median Number of Prior Systemic Therapies (Range) | 2 (1 - 8) |
In all evaluable patients (N = 120) treated with Beleodaq, the overall response rate per central review using IWC was 25.8% (N = 31) (Table 5) with rates of 23.4% for PTCL, NOS and 45.5% for AITL, the two largest subtypes enrolled.
Table 5: Response Analysis per Central Assessment Using IWC in Patients with Relapsed or Refractory PTCL
| Response Rate | Evaluable Patients (N=120) |
|
| N (%) | (95% CI) | |
| CR+PR | 31 (25.8) | 18.3 - 34.6 |
| CR | 13 (10.8) | 5.9 - 17.8 |
| PR | 18 (15.0) | 9.1 - 22.7 |
| CI=confidence interval, CR=complete response, PR=partial response | ||
The median duration of response based on the first date of response to disease progression or death was 8.4 months (95% CI: 4.5 - 29.4). Of the responders, the median time to response was 5.6 weeks (range 4.3 - 50.4 weeks). Nine patients (7.5%) were able to proceed to a stem cell transplant after treatment with Beleodaq.
BELEODAQ®
(Be-leo-dak)
(belinostat) for injection, for intravenous use
Read this Patient Information before you receive treatment with Beleodaq and each time you receive Beleodaq. There may be new information. This leaflet does not take the place of talking to your doctor about your medical condition or your treatment.
What is Beleodaq?
Beleodaq is a prescription medicine used to treat people with a type of cancer called peripheral T-cell Lymphoma (PTCL) that comes back or does not respond to cancer treatment.
It is not known if Beleodaq is safe and effective in children.
What should I tell my doctor before receiving Beleodaq?
Before receiving Beleodaq, tell your doctor about all of your medical conditions, including if you:
Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.
How will I receive Beleodaq?
What are the possible side effects of Beleodaq?
Beleodaq may cause serious side effects, including:
Common side effects of Beleodaq include fatigue, fever, and low red blood cell count.
Tell your doctor if you have any sid e effect that bothers you or that does not go away.
These are not all the possible side effects of Beleodaq. Call your doctor for medical advice about side effects. You can report side effects to FDA at 1-800-FDA-1088.
General information about Beleodaq
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. You can ask your pharmacist or doctor for information about Beleodaq that is written for health professionals.
What are the ingredients in Beleodaq?
Active ingredient: belinostat
Inactive ingredients: L-Arginine
This Patient Information has been approved by the U.S. Food and Drug Administration.
